
https://www.science.org/content/blog-post/more-hua-change-business-plans
# More From Hua - A Change of Business Plans? (December 2011)

## 1. SUMMARY
The article discusses Hua Medicine (Hua Pharmaceuticals), a Chinese company that had previously stated its business model was to in-license drugs already approved and marketed in the US or EU, then get them approved in China within a 4-year timeframe. However, the author notes a significant shift in this strategy: Hua Medicine had just licensed Roche's glucokinase activator program for diabetes treatment, a compound that had not been approved or marketed anywhere and may not have even reached Phase III trials.

This represented a fundamental change from Hua's stated business plan of licensing proven drugs to taking on the risk and expense of developing an unproven compound with a novel mechanism. The author speculates that perhaps diabetes drug approval requirements are less stringent in China than in the US (where cardiovascular safety requirements had become more rigorous), or that safer, already-approved compounds were not available for licensing.

## 2. HISTORY
**Hua Medicine's subsequent trajectory:** After this 2011 licensing deal with Roche, Hua Medicine pursued development of the glucokinase activator (GKA) for diabetes. The lead compound, dorzagliatin (HMS5552), did advance through clinical trials. However, the road proved challenging and longer than the original 4-year timeline suggested.

**Dorzagliatin development and outcomes:** Hua Medicine conducted multiple Phase III clinical trials for dorzagliatin as a treatment for type 2 diabetes. The drug showed mixed results - while it demonstrated efficacy in lowering blood glucose, the trials also revealed challenges with durability of effect and safety profile concerns typical of this mechanism class. Notably, other GKA programs from different companies faced similar issues and several were discontinued.

**Regulatory reality:** The article's speculation about easier approval pathways in China proved overly optimistic. China's regulatory standards, particularly through the NMPA (formerly SFDA), have become increasingly stringent and aligned with international standards, especially for diabetes drugs where cardiovascular safety remains a key concern.

**Business outcome:** As of 2024, dorzagliatin has not received full regulatory approval in China or elsewhere for broad clinical use. The development process extended well beyond the original 4-year projection, taking over a decade with substantial investment costs. Hua Medicine's strategy shift from licensing proven drugs to developing novel compounds represented significantly higher risk than their initial business model.

## 3. PREDICTIONS
- **Prediction that approval might be easier in China due to less pressing safety concerns:** This proved incorrect. China's regulatory environment has become increasingly rigorous, with diabetes drug approval requiring comprehensive cardiovascular safety data, similar to FDA requirements.
  
- **Implicit prediction that the 4-year timeline was achievable:** The actual development timeline extended to over 10 years, far exceeding initial projections.

- **Implication that GKAs might succeed where market was "well-served":** The diabetes market has remained competitive, and GKA mechanism has faced challenges across multiple companies, not just regulatory hurdles but also clinical efficacy and safety profile issues.

## 4. INTEREST
**Score: 6/10**

This article is moderately interesting as it captures a transitional moment in China's pharmaceutical industry strategy and illustrates the gap between business plans and clinical/regulatory realities. The central tension between expedited timelines and drug development complexity remains relevant to biotech business models today. However, the story had limited broader industry impact compared to other breakthrough technologies or policy shifts.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20111222-more-hua-change-business-plans.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_